Cantor Equity Partners VII is a freshly-IPO'd special purpose acquisition company that closed its initial public offering on June 18, 2026, raising $250 million in trust at $10.00 per unit with 25,000,000 Class A ordinary shares outstanding, and the company is in the search stage with the deal-or-liquidate clock now running. The Cantor Fitzgerald-affiliated SPAC is the seventh in the Cantor SPAC series, and the company is operating against the same Cantor SPAC framework that the prior six Cantor SPACs have operated against, including the unit structure, the trust-per-share floor, the warrant economics, and the sponsor founder-share economics. The fiscal second quarter is the first full quarter of public-company reporting, and the principal question for the next twelve to twenty-four months is whether the sponsor identifies a target that institutional investors are willing to leave the trust for at the time of the de-SPAC vote.
The numbers tell the story with the kind of mechanical precision the SPAC equity offers. The trust account at quarter-end held $250,228,757 in available-for-sale debt securities, with the per-share redemption value of $10.16 reflecting the accrued interest on the trust investments. The 25,000,000 Class A ordinary shares are subject to possible redemption, and the redemption value of the trust represents the floor for the equity. The current share price of $10.10 is trading at a 0.6 percent discount to the trust per-share floor, which is one of the tighter discounts in the Cantor SPAC series and which reflects the market's near-certainty of the trust-floor protection through the deal-or-liquidate window.
The share count structure is the second structural feature. The 25,000,000 Class A ordinary shares were issued in the IPO at $10.00 per unit, and the Class B ordinary shares were surrendered at the IPO closing. The over-allotment option is available for 3,750,000 additional Class A ordinary shares, and the sponsor has not yet exercised the over-allotment. The warrant structure is the third structural feature, with each whole warrant exercisable for one Class A ordinary share at $11.50 per share, and the warrant economics are the secondary trading instrument that the institutional investors use to express their view on the deal-or-liquidate outcome.
The deal-or-liquidate clock is the binding constraint the equity offers the buy-side. The SPAC must complete an initial business combination within 24 months of the IPO closing, which puts the deadline at June 18, 2028. The sponsor has the option to extend the deadline by depositing additional funds, but the default deadline is the binding constraint. The principal question is whether the sponsor identifies a target that institutional investors are willing to approve, and whether the deal closes before the deadline.
The question the next four quarters resolve is whether the company makes meaningful progress toward a de-SPAC announcement, and whether the institutional investors are willing to leave the trust for the announced target. A 2026 fourth-quarter or 2027 first-quarter update that announces a definitive de-SPAC agreement would confirm the SPAC is on a productive trajectory, and a continued period without a de-SPAC announcement would force the market to reprice the equity for a more modest terminal value.